TONGHUA GOLDEN-HORSE PHARMACEUTICAL INDUSTRY CO,LTD Financials Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd
Equities
000766
CNE000000735
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.86 CNY | -0.42% |
|
+9.91% | -5.42% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6,630 | 6,321 | 3,151 | 4,591 | 5,093 | 19,272 |
| Enterprise Value (EV) 1 | 6,912 | 7,401 | 4,745 | 6,142 | 6,554 | 20,796 |
| P/E ratio | 20.2 x | -3.1 x | -8.81 x | 119 x | 176 x | 399 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.17 x | 3.2 x | 2.83 x | 3.03 x | 3.46 x | 13.1 x |
| EV / Revenue | 3.3 x | 3.74 x | 4.27 x | 4.05 x | 4.46 x | 14.1 x |
| EV / EBITDA | 21.3 x | 64.9 x | -17 x | 33.8 x | 33.1 x | 95.3 x |
| EV / FCF | 285 x | -557 x | 56.9 x | 54.8 x | 65.6 x | 221 x |
| FCF Yield | 0.35% | -0.18% | 1.76% | 1.83% | 1.52% | 0.45% |
| Price to Book | 1.41 x | 2.4 x | 1.39 x | 1.99 x | 2.18 x | 5.31 x |
| Nbr of stocks (in thousands) | 9,66,495 | 9,66,495 | 9,66,495 | 9,66,495 | 9,66,495 | 9,66,495 |
| Reference price 2 | 6.860 | 6.540 | 3.260 | 4.750 | 5.270 | 19.94 |
| Announcement Date | 09/04/19 | 28/04/20 | 26/04/21 | 18/04/22 | 18/04/23 | 18/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2,095 | 1,977 | 1,112 | 1,515 | 1,471 | 1,473 |
| EBITDA 1 | 324.1 | 114 | -278.7 | 181.5 | 198.2 | 218.1 |
| EBIT 1 | 257.3 | 46.27 | -346.2 | 112.5 | 127 | 143.4 |
| Operating Margin | 12.28% | 2.34% | -31.14% | 7.43% | 8.64% | 9.73% |
| Earnings before Tax (EBT) 1 | 409.2 | -2,013 | -355.8 | 59.62 | 50.17 | 54.86 |
| Net income 1 | 330.9 | -2,042 | -359.5 | 35.27 | 30.15 | 43.93 |
| Net margin | 15.8% | -103.27% | -32.33% | 2.33% | 2.05% | 2.98% |
| EPS 2 | 0.3400 | -2.113 | -0.3700 | 0.0400 | 0.0300 | 0.0500 |
| Free Cash Flow 1 | 24.23 | -13.29 | 83.36 | 112.2 | 99.93 | 94.21 |
| FCF margin | 1.16% | -0.67% | 7.5% | 7.4% | 6.79% | 6.39% |
| FCF Conversion (EBITDA) | 7.48% | - | - | 61.79% | 50.42% | 43.19% |
| FCF Conversion (Net income) | 7.32% | - | - | 317.99% | 331.42% | 214.45% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 09/04/19 | 28/04/20 | 26/04/21 | 18/04/22 | 18/04/23 | 18/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 282 | 1,080 | 1,594 | 1,551 | 1,461 | 1,524 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.87 x | 9.472 x | -5.72 x | 8.545 x | 7.372 x | 6.986 x |
| Free Cash Flow 1 | 24.2 | -13.3 | 83.4 | 112 | 99.9 | 94.2 |
| ROE (net income / shareholders' equity) | 7.18% | -55.1% | -14.5% | 1.46% | 1.24% | 1.84% |
| ROA (Net income/ Total Assets) | 2.74% | 0.54% | -4.47% | 1.46% | 1.7% | 1.95% |
| Assets 1 | 12,062 | -3,77,638 | 8,036 | 2,412 | 1,771 | 2,256 |
| Book Value Per Share 2 | 4.870 | 2.720 | 2.350 | 2.390 | 2.420 | 3.760 |
| Cash Flow per Share 2 | 0.3300 | 0.2900 | 0.5300 | 0.3100 | 0.3500 | 0.2900 |
| Capex 1 | 74.4 | 61 | 19.2 | 25.5 | 23.7 | 26.7 |
| Capex / Sales | 3.55% | 3.08% | 1.72% | 1.68% | 1.61% | 1.81% |
| Announcement Date | 09/04/19 | 28/04/20 | 26/04/21 | 18/04/22 | 18/04/23 | 18/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -5.42% | 2.52B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- 000766 Stock
- Financials Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd
